TERLIVAZ is the first and only FDA-approved product indicated to improve kidney function in adults with HRS with rapid reduction in kidney function,4 an acute and life-threatening condition requiring hospitalization.5 TERLIVAZ is not approved in
Paul J. Thuluvath, MD, will present findings from a pooled analysis of Mallinckrodt's three prospective, randomized, placebo-controlled clinical studies in patients with HRS (OT-0401, REVERSE, and CONFIRM) to examine whether there was any impact of race (White vs. non-White) on treatment response to TERLIVAZ.1 HRS reversal - defined as the proportion of patients achieving a serum creatinine level of 1.5 mg/dL while on treatment including up to 24 hours after the last dose of study drug - was examined by race and assessed for the potential to predict treatment response.1
A post-hoc analysis of the Phase III CONFIRM trial - which evaluated maximum change and time of maximum change in mean arterial pressure, heart rate (HR) and systolic and diastolic blood pressure (SBP and DBP) with TERLIVAZ treatment - will be presented by
Additionally, results from a real-world analysis of the impact of hospital size on patient outcomes among those with chronic liver disease (CLD) and acute kidney injury or HRS will be presented by
About Hepatorenal Syndrome (HRS)
Hepatorenal syndrome (HRS) involving rapid reduction in kidney function4 is an acute and life-threatening condition that occurs in people with advanced liver disease.5 HRS is classified into two distinct types - a rapidly progressive type that leads to acute renal failure where patients are typically hospitalized for their care and a more chronic type that progresses over weeks to months.5 HRS involving rapid reduction in kidney function4 is estimated to affect between 30,000 and 40,000 Americans annually.6,7 If left untreated, HRS with rapid reduction in kidney function4 has a median survival time of approximately two weeks and greater than 80 percent mortality within three months.8
ABOUT MALLINCKRODT
Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients.
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the
CAUTIONARY STATEMENTS RELATED TO FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, including with regard to TERLIVAZ, its potential to improve health and treatment outcomes, and its potential impact on patients. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: the impact of Mallinckrodt's pending Chapter 11 cases; satisfaction of, and compliance with, regulatory and other requirements; actions of regulatory bodies and other governmental authorities; changes in laws and regulations; issues with product quality, manufacturing or supply, or patient safety issues or adverse side effects or adverse reactions associated with TERLIVAZ and other risks identified and described in more detail in the 'Risk Factors' section of Mallinckrodt's most recent Annual Report on Form 10-K and other filings with the
Contact:
Tel: 954-816-6003
Email: mediainquires@grcomms.com
Tel: 314-654-3638
Email: daniel.speciale@mnk.com
(C) 2023 Electronic News Publishing, source